Mundipharma International Ltd - Strategic SWOT Analysis Review

February 2020 | 31 pages | ID: M7F78E13120EN
GlobalData

Abstracts

Mundipharma International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Mundipharma International Ltd (Mundipharma) conducts research and develops products for the treatment pain management, respiratory, cancer and inflammatory conditions. The company commercializes and launches products within Europe and rest of the world. Mundipharma offers products through network of subsidiaries, independent associated companies, partners and joint ventures. The company’s network includes Napp Pharmaceuticals, Norpharma and the Mundipharma independent associated companies. The company provides its services to patients, healthcare professionals and health systems worldwide. It has operations in Australia, Japan, New Zealand, Russia, Singapore, Philippines, South Africa, South Korea, Canada, China and USA. Mundipharma is headquartered in Cambridge, the UK.

Mundipharma International Ltd Key Recent Developments

Sep 04,2019: Cidara and Mundipharma sign rezafungin drug development deal
Jun 14,2019: Egis Pharmaceuticals to launch Mundipharma’s Pelmeg in CEE markets
Feb 18,2019: Mundipharma appoints Patrice Grand as European Director of Corporate Communications

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Mundipharma International Ltd - Key Facts
Mundipharma International Ltd - Key Employees
Mundipharma International Ltd - Key Employee Biographies
Mundipharma International Ltd - Major Products and Services
Mundipharma International Ltd - History
Mundipharma International Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Mundipharma International Ltd - Business Description
Mundipharma International Ltd - Corporate Strategy
Mundipharma International Ltd - SWOT Analysis
SWOT Analysis - Overview
Mundipharma International Ltd - Strengths
Mundipharma International Ltd - Weaknesses
Mundipharma International Ltd - Opportunities
Mundipharma International Ltd - Threats
Mundipharma International Ltd - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Mundipharma International Ltd, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Sep 04, 2019: Cidara and Mundipharma sign rezafungin drug development deal
Jun 14, 2019: Egis Pharmaceuticals to launch Mundipharma’s Pelmeg in CEE markets
Feb 18, 2019: Mundipharma appoints Patrice Grand as European Director of Corporate Communications

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Mundipharma International Ltd, Key Facts
Mundipharma International Ltd, Key Employees
Mundipharma International Ltd, Key Employee Biographies
Mundipharma International Ltd, Major Products and Services
Mundipharma International Ltd, History
Mundipharma International Ltd, Subsidiaries
Mundipharma International Ltd, Joint Venture
Mundipharma International Ltd, Key Competitors
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Mundipharma International Ltd, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Verona Pharma Plc
Vernalis R&D Ltd
Abbott (UK) Holdings Ltd